GlassScriptPhysician profile
David Dorf
NPI 1124034152
$892.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $218.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.39 | 2019-2020 | |
| Novo Nordisk INC | $131.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $115.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $78.67 | 2019-2020 | |
| Lilly USA, LLC | $53.05 | 2019-2020 | |
| Pfizer INC. | $47.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.37 | 2019 | |
| Abbott Laboratories | $20.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.27 | 2019 | |
| Allergan, INC. | $16.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.25 | 2020 | |
| Sanofi Pasteur INC. | $12.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.